Linagliptin

Linagliptin

Drug monograph · NCLEX study reference
Trade names	Tradjenta
Therapeutic class	Antidiabetic
Pharmacologic class	DPP-4 inhibitor
Onset / peak / duration	Once-daily effect.
Half-life / level	Long terminal half-life; no routine level.
Routes	PO (oral)
High-alert (ISMP)	No
Black box warning	None
Antidote / reversal	None.
Pregnancy / lactation	Limited data.

Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.

Linagliptin (brand name Tradjenta) — Antidiabetic; DPP-4 inhibitor.

Identification

• Therapeutic class: Antidiabetic.
• Pharmacologic class: DPP-4 inhibitor.

Pharmacology

• Mechanism of action: Same incretin enhancement as sitagliptin; primarily nonrenal elimination.
• Onset / peak / duration: Once-daily effect.
• Half-life / therapeutic level: Long terminal half-life; no routine level.

Clinical use

• Indications: Type 2 diabetes.
• Usual dose, route, frequency: 5 mg PO once daily.
• Maximum dose / adjustments: No renal or hepatic dose adjustment needed.

Safety

• Contraindications: Type 1 diabetes, serious hypersensitivity history.
• Black box warning: None.
• Interactions: Strong CYP3A4 and P-gp inducers reduce levels; additive hypoglycemia with secretagogues.
• Pregnancy / lactation: Limited data.
• High-alert: No.

Adverse effects

• Common side effects: Nasopharyngitis, headache.
• Serious effects to report: Pancreatitis, severe joint pain, hypersensitivity.
• Antidote / reversal: None.

Nursing process

• Assessment before administration: Pancreatitis history.
• Interventions during therapy: Useful when renal dosing is a concern.
• Monitor: A1c.
• Evaluation / expected outcome: Glycemic control.

Patient teaching

• Patient teaching: Report severe abdominal pain.
• Notify provider if: Severe stomach or joint pain.
• Administration tips: With or without food.